Methods of diagnosis and therapeutic targeting of clinically intractable malignant tumors
AssigneeOncoScar LLC
InventorsLlew Keltner, Guennadi V. Glinskii
Life of this patent
Estimating the term…
Abstract
The present disclosure is directed to methodologies or technologies for generating a predictor of a disease state (e.g. cancer-therapy efficacy status, cancer therapy progress, cancer prognosis, cancer diagnosis, therapy failure, relapse, recurrence, and the like) based on genomic and proteomic signatures, gene expression, and pathways & networks activation of endogenous human stem cell-associated retroviruses (SCAR). This disclosure is also directed to methods of targeting, designing, and using treatments for clinically intractable malignant tumors.
Claims8
1-18. (canceled)
A system for diagnosing cancer or predicting cancer-therapy outcome in a subject, comprising:
- circuitry configured to generate target marker information responsive to one or more inputs indicative of a genomic signature pathway and one or more inputs indicative of a proteomic signature pathway of endogenous human Stem Cell-Associated Retroviruses (SCAR);
- and
- circuitry configured to generate aberrant object information responsive to comparing at least one input indicative of an expression levels and at least one input indicative of a sequence of a biological sample with target marker information.
20-23. (canceled)
A method for diagnosing cancer or predicting cancer-therapy outcome in a subject, comprising:
- concurrently screening a biological sample for a presence of an aberrant sequences and an aberrant expression level of one or more target markers associated with a pathway involving genomic and proteomic signatures of endogenous human Stem Cell-Associated Retroviruses (SCAR);
- scoring a sequence associated with the biological sample as aberrant when the quality of the sequence is distinct compared with a reference sequence;
- and
- scoring an expression level associated with the biological sample as being aberrant when a detected expression level is above a target threshold coefficient.
25-60. (canceled)
A method for treating cancer in a subject in need thereof, the method comprising detecting SCARS pathway activation caused by a transcriptionally active Stem Cell-Associated Retroviruses (SCARs) locus or a plurality of transcriptionally active SCARS loci in cancer cells obtained from the subject, wherein the method comprises
- detecting the expression of each of the genes in a set of human genes selected from (i) the set of 74 genes listed in FIG. 19A, and (ii) the set of 55 genes listed in FIG. 19B, or both;
- determining SCARs pathway activation in the cancer by a method comprising comparing the expression of each gene in the set of genes in (i) and/or (ii) to a reference gene expression value, which is the expression of each gene in nonmalignant somatic tissues, and determining a correlation coefficient for expression of the genes in the cancer and the nonmalignant somatic tissues,
- wherein a positive correlation coefficient indicates no SCARS pathway activation and a negative correlation coefficient indicates SCARS pathway activation;
- and
- administering to the subject with SCARs pathway activation in the cancer a therapeutic treatment effective to suppress LTR7/HERVH loci in the cancer cells of the subject.
Dependencies are inferred from the claim text.